Monitor the May 18, 2026 trial start for developments in the FIRDAPSE patent litigation. A delay reduces near-term downside risk but prolongs uncertainty around generic competition.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 19 $22.33entry
- T+1 · 8mo ago +2.06%α +3.80% · $22.79
- T+5 · 8mo ago +8.60%α +10.81% · $24.25
- T+20 · 7mo ago +17.60%α +9.98% · $26.26
- T+60 · 5mo ago +40.44%α +26.10% · $31.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals filed an amended 8-K to correct a scrivener's error in the signature date of a prior filing. The amendment confirms a court order delaying the bench trial with Hetero USA, Inc. over FIRDAPSE patent validity from March 23, 2026 to May 18, 2026. No other changes were made.
Key Facts
- Amendment No. 1 to Form 8-K filed to correct a scrivener's error in the signature date of the original March 18, 2026 filing.
- District Court for the District of New Jersey delayed the bench trial in the patent litigation with Hetero USA, Inc. from March 23, 2026 to May 18, 2026.
- The litigation concerns the validity of Catalyst's Orange Book-listed patents for FIRDAPSE, which expire in 2032, 2034, and 2037.
- No other changes were made to the original filing; the delay does not reflect a ruling on the merits of the case.
Financial Impact
No immediate financial impact disclosed. Trial delay extends uncertainty but avoids near-term risk of adverse ruling.
Risk Factors
- Adverse ruling in the patent trial could invalidate key FIRDAPSE patents and open the door to generic competition.
- Extended litigation increases legal expenses and delays resolution of market exclusivity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001193125-26-114764 |
| Document: 0001193125-26-114764-index-headers.html | 0001193125-26-114764 |
| Document: 0001193125-26-114764-index.html | 0001193125-26-114764 |
| Document: 0001193125-26-114764.txt | 0001193125-26-114764 |
Track record
16 reports on CPRX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers